Dashboard
Curated content
All companies
Job board
Funding rounds
Exits
Matching tool
Investment heatmap
Companies
Nirvana Life Sciences
Save
Nirvana Life Sciences
Is focused on developing medical.
Market cap
€2.4m
Enterprise valuation
€2m
(Public information from Sep 2024)
Share price
CAD0.075 NIRV.CN
Vancouver British Columbia (HQ)
http://nirvanalifesciences.com
https://www.facebook.com/nirvanalifesciences
https://www.linkedin.com/company/nirvanalifesciencesinc/
B2B
manufacturing
health
biotechnology
hard tech
biotechnology
biotech and pharma
psychedelic drugs
Overview
Similar companies
Analytics
Notes
Job openings
Innovations (0)
Financials
Estimates*
Edit
Revenues, earnings & profits over time
CAD
2020
2021
2022
2023
EBITDA
(<1m)
(<1m)
3.4m
(1.2m)
Profit
(<1m)
(<1m)
(5.7m)
(1.5m)
EV / EBITDA
-
-
1.2x
-0.9x
R&D budget
-
-
<1m
<1m
Nirvana Life Sciences funding
Nirvana Life Sciences investors
Edit
Date
Investors
Amount
Round
Feb 2021
ThreeD Capital
$450k
Early VC
Mar 2022
N/A
N/A
IPO
Jun 2022
*
ThreeD Capital
N/A
Acquisition
Total Funding
€409k
Recent News about Nirvana Life Sciences
Edit